Related Experiment Video
Updated: Jul 5, 2025
Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery
Published on: July 18, 2019
Adjuvant convection-enhanced delivery for the treatment of brain tumors
Daniel Kreatsoulas1, Mark Damante2, Santino Cua2
1Department of Neurological Surgery, The Ohio State University Wexner Medical Center, The Ohio State University, N1019 Doan Hall, 410 W 10Th Avenue, Columbus, OH, 43210, USA. daniel.kreatsoulas@osumc.edu.
Background:
Malignant gliomas are a therapeutic challenge and remain nearly uniformly fatal. While new targeted chemotherapeutic agentsagainst malignant glioma have been developed in vitro, these putative therapeutics have not been translated into successful clinical treatments. The lack of clinical effectiveness can be the result of ineffective biologic strategies, heterogeneous tumor targets and/or the result of poortherapeutic distribution to malignant glioma cells using conventional nervous system delivery modalities (intravascular, cerebrospinal fluid and/orpolymer implantation), and/or ineffective biologic strategies.
Methods:
The authors performed a review of the literature for the terms "convection enhanced delivery", "glioblastoma", and "glioma". Selectclinical trials were summarized based on their various biological mechanisms and technological innovation, focusing on more recently publisheddata when possible.
Results:
We describe the properties, features and landmark clinical trials associated with convection-enhanced delivery for malignant gliomas.We also discuss future trends that will be vital to CED innovation and improvement.
Conclusion:
Efficacy of CED for malignant glioma to date has been mixed, but improvements in technology and therapeutic agents arepromising.
Insights
Convection-enhanced delivery (CED) shows promise for treating malignant gliomas, despite mixed results. Ongoing technological and therapeutic advancements are crucial for improving its effectiveness in brain tumor treatment.
Area of Science:
- Neuro-oncology
- Drug Delivery Systems
- Biomedical Engineering
Background:
- Malignant gliomas are aggressive brain tumors with poor prognoses.
- Current chemotherapeutic agents show limited clinical efficacy due to biological and distribution challenges.
- Conventional delivery methods struggle to effectively target glioma cells within the central nervous system.
Purpose of the Study:
- To review the literature on convection-enhanced delivery (CED) for malignant gliomas.
- To summarize key clinical trials and technological innovations in CED.
- To discuss future directions for CED improvement.
Main Methods:
- Literature review using keywords: "convection enhanced delivery", "glioblastoma", and "glioma".
- Analysis of select clinical trials focusing on biological mechanisms and technological advancements.
- Emphasis on recent data and landmark studies.
Main Results:
- Description of properties and features of CED for malignant gliomas.
- Summary of landmark clinical trials evaluating CED.
- Identification of future trends critical for CED innovation.
Conclusions:
- The efficacy of CED for malignant gliomas has yielded mixed outcomes.
- Advancements in CED technology and therapeutic agents offer promising future potential.
- Continued innovation is essential for enhancing CED's role in glioma treatment.
